Advanced Pathophysiology of Acute Myelogenous Leukemia (AML) – NURS-6501 Week 2 Case Study Scenario SOLVED
Advanced Pathophysiology of Acute Myelogenous Leukemia (AML) – NURS-6501 Week 2 Case Study Scenario
Case Study 2: Advanced Pathophysiology of Acute Myelogenous Leukemia (AML)
A 45-year-old male presents to the hematology clinic with symptoms of progressive fatigue,
frequent bruising, and recurrent nosebleeds over the past few weeks. On physical examination,
he appears pale and has petechiae on his lower extremities. Blood tests reveal a white blood cell
count of 50,000/mm³ with 60% blasts, hemoglobin of 8.5 g/dL, and platelets of 25,000/mm³. A
bone marrow biopsy confirms the diagnosis of AML, showing hypercellularity with 70%
myeloblasts. Cytogenetic analysis reveals a FLT3-ITD mutation, placing him in the intermediate-
risk category.
In 1 -2 pages, answer the questions below in detail. You must use current evidence-based
resources to support your answers. Follow APA guidelines. Follow the grading rubric.
Questions:
1.What is the primary cellular abnormality in AML?
2.How does the accumulation of leukemic blasts affect normal hematopoiesis?
3.What role do genetic mutations play in the development of AML?
4.Why do patients with AML often present with symptoms like fatigue, infections, and
bleeding?
5.What is the significance of Auer rods in the diagnosis of AML?
6.What is the impact of AML on the immune system?
7.How do treatment strategies target the pathophysiological mechanisms of AML?
Advanced Pathophysiology of Acute Myelogenous Leukemia (AML) – NURS-6501 Week 2 Case Study Scenario
Case Study Analysis
The severe blood malignancy known as acute myelogenous leukemia (AML) impairs the bone marrow’s capacity to produce healthy blood cells. The symptoms of a 45-year-old male patient include increased fatigue, easy bruising, and frequent nosebleeds. Laboratory tests show low hemoglobin levels, decreased platelet counts, and an increased white blood cell count with notable blast cells. The diagnosis of AML is confirmed by a bone marrow biopsy, which shows hypercellularity with a significant proportion of myeloblasts. He is classified as intermediate-risk due to the FLT3-ITD mutation, which is revealed by additional genetic investigation. Understanding the anomalies in AML cells, as well as their genetic causes and immunological effects, is essential for the diagnosis and treatment of this illness.
Myeloblasts are immature white blood cells that do not go through the normal maturation processes, and their unrestrained multiplication is the cause of AML. The development of these immature cells is disrupted by this shortage; as they aggregate in the bone marrow, they prevent the generation of healthy platelets, white blood cells, and red blood cells (Döhner et al., 2022). Patients suffer from a range of symptoms as a result, from fatigue to heightened susceptibility to infections and bleeding episodes. Hematopoiesis, the process by which blood cells normally grow, is severely disrupted by the quantity of leukemic blasts.
The excessive accumulation within investors obstructs adequate production rates for regular blood cell types leading to anemia which often causes lethargy due to decreased oxygen transport capabilities in the body. Furthermore, neutropenia results from insufficient functional white blood cell quantity contributing greatly to susceptibility toward infections while thrombocytopenia makes avenue for bruising easily despite minimal trauma hence explaining phenomena such as petechiae or recurrent nasal hemorrhages observed in this patient case (Borthakur & Kantarjian, 2021).
ORDER A HUMAN-WRITTEN PAPER HERE
Genetic mutations play a key role in AML development. The FLT3-ITD mutation found in this patient is associated with increased cell proliferation and poor prognosis. This mutation causes continuous activation of signaling pathways that promote cancer cell survival and growth. Other mutations, such as NPM1 or RUNX1, may also contribute to disease progression and treatment resistance (Williams et al., 2021). Identifying these mutations helps in selecting the best treatment approach.
Patients with AML often experience fatigue, infections, and bleeding due to the shortage of normal blood cells. Fatigue results from anemia, as fewer red blood cells are available to carry oxygen throughout the body. Frequent infections occur because leukemic blasts replace normal white blood cells, which weakens the immune system. Bleeding problems arise from the lack of platelets, leading to symptoms like easy bruising, nosebleeds, and petechiae, as seen in this patient (Döhner et al., 2022).
Auer rods are important in diagnosing AML. They are rod-shaped structures found inside myeloblasts and are made up of fused lysosomes containing myeloperoxidase, an enzyme specific to myeloid cells. The presence of Auer rods confirms AML and helps differentiate it from other types of leukemia.
AML significantly affects the immunological system. A shortage of healthy white blood cells weakens the immunological response. This makes infections more likely, even from little wounds or common microorganisms. Infections become more severe and more difficult to treat when the body’s defenses against viruses and fungi are compromised (Barrett, 2020). Inflammation linked to AML can also further impair immunological function.
The molecular level of AML is the focus of treatment. Chemotherapy is a common treatment used to destroy leukemic blasts and restore normal blood cell production. One kind of targeted drug used to slow the disease’s progression and stop abnormal FLT3 signaling in patients with the FLT3-ITD mutation is midostaurin. In order to reestablish normal hematopoiesis and increase survival prospects, some patients may need a bone marrow transplant to replace damaged cells with healthy donor cells (Döhner et al., 2022).
Conclusively, AML is a serious blood malignancy brought on by myeloblasts growing out of control. Fatigue, infections, and bleeding are some of the symptoms caused by the disease’s disruption of normal blood cell synthesis. Genetic abnormalities like FLT3-ITD are important in the development of AML and have an impact on therapy choices. The presence of Auer rods confirms AML diagnosis, and the immune system is severely weakened due to a lack of functional white blood cells. Treatment strategies focus on eliminating leukemic cells through chemotherapy, targeted therapy, and bone marrow transplantation. Understanding the underlying cellular processes in AML is crucial for effective management and patient education Advanced Pathophysiology of Acute Myelogenous Leukemia (AML) – NURS-6501 Week 2 Case Study Scenario.
References
Barrett, A. J. (2020). Acute myeloid leukaemia and the immune system: Implications for immunotherapy. British Journal of Haematology, 188(1), 147-158. https://doi.org/10.1111/bjh.16310
Borthakur, G., & Kantarjian, H. (2021). Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer Journal, 11(6). https://doi.org/10.1038/s41408-021-00503-6
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., Larson, R. A., Levine, R. L., Miyazaki, Y., Niederwieser, D., Ossenkoppele, G., Röllig, C., Sierra, J., Stein, E. M., Tallman, M. S., … Löwenberg, B. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 140(12), 1345-1377. https://doi.org/10.1182/blood.2022016867
Williams, L., Doucette, K., Karp, J. E., & Lai, C. (2021). Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 56(7), 1535-1549. https://doi.org/10.1038/s41409-021-01214-z. Advanced Pathophysiology of Acute Myelogenous Leukemia (AML) – NURS-6501 Week 2 Case Study Scenario
